DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Wolfgang Rattay - 1 Bayer - 1 BlueRock - 1 Britain's - 1 Jennifer Doudna - 1 Ludwig Burger - 1 Miranda Murray - 1 Mark Potter - 1
Top related locs:
Leverkusen Germany FRANKFURT Australia San Francisco Bay
Top related orgs:
Bayer AG - 1 REUTERS - 1 Bayer - 1 Cambridge University - 1 South Korea's - 1 CHA Hospital - 1 Cyto Therapeutics - 1 Chinese Academy of Sciences - 1

Search resuls for: "Mammoth Biosciences"


2 mentions found


☆ Bayer claims early lead in Parkinson's stem cell therapy
  + stars: | 2023-06-28 | by ( Ludwig Burger | ) www.reuters.com   time to read: +3 min
Some of this work is done by Britain's' Cambridge University, South Korea's Bundang CHA Hospital, International Stem Cell Corp's (ISCO.PK) Cyto Therapeutics in Australia, the Chinese Academy of Sciences, Harvard University and Japan's Kyoto University Hospital. For BlueRock's experimental therapy, researchers took induced pluripotent stem cells, which are modified to regain the ability to form any type of specialised tissue, and transformed them into dopamine-producing nerve cells. When surgically implanted into the brain of a person with Parkinson's disease, the therapeutic cells are designed to restore neural networks destroyed by the disease. Initial trial results showed the cells multiplied and started making dopamine, an important brain signalling molecule which is lacking in Parkinson's patients. Parkinson's, for which there is no cure and which affects more than 10 million people worldwide, causes progressive brain damage.
Persons: Wolfgang Rattay, Bayer, BlueRock, Britain's, Jennifer Doudna, Ludwig Burger, Miranda Murray, Mark Potter Organizations: Bayer AG, REUTERS, Bayer, Cambridge University, South Korea's, CHA Hospital, Cyto Therapeutics, Chinese Academy of Sciences, Harvard University, Japan's Kyoto University Hospital, BlueRock Therapeutics, Mammoth Biosciences, Thomson Locations: Leverkusen, Germany, FRANKFURT, Australia, San Francisco Bay
☆ We went inside the lab at Vertex, a company that dodged the market downturn to become one of the best-performing biotechs of 2022
  + stars: | 2022-09-21 | by ( Andrew Dunn | ) www.businessinsider.com   time to read: +10 min
A mosaic of human cells inside Vertex Pharmaceuticals' cell and gene-therapy laboratory. The four-story, 267,000-square-foot space is home to Vertex's cell and gene-therapy unit, with about 375 people now residing in the modern-industrial building. That has led to going after unrelated diseases like sickle cell, diabetes, muscular dystrophy, kidney disease, and pain. For instance, Vertex's approach to sickle cell is led by its CRISPR gene-editing program. Vertex PharmaceuticalsThe next test of Vertex's strategy will be an experimental treatment called exa-cel, its CRISPR gene-editing program for sickle cell.
0 next >>
Total: 2